A Clinical Study of Dual-Target, Universal CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus

NCT07444307 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Lupus Erythematosus (SLE)

Interventions

DRUG: QT-019B Cell Injection

Sponsor

Hangzhou Qihan Biotech Co., Ltd.